Profiling of EGFR mRNA and protein expression in 471 breast cancers compared with 10 normal tissues: A candidate biomarker to predict EGFR inhibitor effectiveness

International Journal of Cancer

Volumn 131, Issue 4, 2012, Pages 1009-1010

  Meseure, Didier ^a   Vacher, Sophie ^a   Drak Alsibai, Kinan ^a   Trassard, Martine ^a   Susini, Aurelie ^a   Le Ray, Claudine ^a   Lerebours, Florence ^a   Le Scodan, Romuald ^a   Spyratos, Frederique ^a   Marc Guinebretiere, Jean ^a   Lidereau, Rosette ^a   Bieche, Ivan ^a  

^a INSTITUT CURIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TATA BINDING PROTEIN;

BREAST CANCER; CELL MEMBRANE; COLORECTAL CANCER; CONTROLLED STUDY; CYTOPLASM; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FREQUENCY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LETTER; LUNG CANCER; PREDICTION AND FORECASTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN OVEREXPRESSION; PROTEIN UNDEREXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; HUMANS; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RNA, MESSENGER; TUMOR MARKERS, BIOLOGICAL;

EID: 84862541672     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.26434     Document Type: Letter

References (10)

1. Citri A, Yarden Y,. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 2006; 7: 505-16. (Pubitemid 44036456)
2. Camp ER, Summy J, Bauer TW,. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Cancer Res 2005; 11: 397-405. (Pubitemid 40075820)
3. Podo F, Buydens LM, Degani H, Hilhorst R, Klipp E, Gribbestad IS, Van Huffel S, van Laarhoven HW, Luts J, Monleon D, Postma GJ, Schneiderhan-Marra N, et al. FEMME Consortium. Triple-negative breast cancer: present challenges and new perspectives. Mol Oncol 2010; 4: 209-29.
4. Alvarez RH, Valero V, Hortobagyi GN,. Emerging targeted therapies for breast cancer. J Clin Oncol 2010; 28: 3366-79.
5. Robertson KW, Reeves JR, Smith G, Keith WN, Ozanne BW, Cooke TG, Stanton PD,. Quantitative estimation of epidermal growth factor receptor and c-erbB2 in human breast cancer. Cancer Res 1996; 56: 3823-30. (Pubitemid 26272035)
6. Bieche I, Onody P, Tozlu S, Driouch K, Vidaud M, Lidereau R,. Prognostic value of ERBB Family mRNA expression in breast carcinomas. Int J Cancer 2003; 106: 758-65. (Pubitemid 36993401)
7. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, Beijersbergen RL, Mills GB, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402. (Pubitemid 47539306)
8. Eichhorn PJ, Gili M, Scaltriti M, Serra V, Guzman M, Nijkamp W, Beijersbergen RL, Valero V, Seoane J, Bernards R, Baselga J,. Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 2008; 68: 9221-30.
9. Abd El-Rehim, Pinder SE, Paish CE, Bell JA, Rampaul RS, Blamey RW, Robertson JFR, Nicholson RI, Ellis IO,. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer 2004; 91: 1532-42. (Pubitemid 39486359)
10. Kreike B, van Kouwenhove M, Horlings H, Weigelt B, Peterse H, Bartelink H, van de Vijver MJ,. Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas. Breast Cancer Res 2007; 9: R65.